The University of Windsor, in partnership with Shogun Maitake Canada, unveils breakthrough research set to potentially reshape cancer care for millions of patients across North America through mushrooms certified by Health Canada.
The findings focus on the powerful health benefits of Odaira Black Maitake Extract (OBME), which induces cell death in a dose and time-dependent manner, meaning that higher concentrations and longer treatment durations with OBME result in a significant reduction in cancerous cells and an increase in cancer cell death.
Shogun Maitake is affiliated with leading doctors, universities, and medical institutions across multiple countries, all of whom are conducting research and clinical trials on OBME.
The next phase of the project will further assess the effectiveness of OBME in combination with immunotherapy to support more patients on their cancer journeys.
Led by Dr Siyaram Pandey, University of Windsor Department Head and graduate students, the team explored the Anticancer Activity of Odaira Black Maitake Extract-Prothera on multiple forms of cancer, which is known to possess many health benefits from its high β-glucan (Beta-glucan) content.
Dr Pandey and his team's findings indicate that OBME triggers cell suicide in cancer cells, boosts the immune system response against cancer cells, reduces tumour growth and has the potential to enhance the efficacy of current chemotherapeutics when combined and thus decreasing treatment toxicity in patients and improving their overall quality of life.
Owing to the fragility of Black Maitake mushrooms, Shogun Maitake, a premier supplier of high-quality Maitake mushrooms and mushroom products sold in Asia and North America, is leading the charge in OBME production through its London, Ontario, facility with the most optimal growing conditions.
To distribute the Black Maitake mushroom, Shogun Maitake Canada, a trusted source since 2016, has released its latest revolutionary supplement that has anti-cancer properties, Shogun Maitake EX, with the optimal and potent dosage of Odaira Black Maitake Extract (OBME) supported by the University of Windsor's groundbreaking research in the benefits of maitake immunotherapy in cancer care and other diseases.
The combination care of Shogun Black Maitake includes products Prothera and EX, at an accessible price point, reinforcing Shogun Maitake's company value to ensure quality and accessibility for those in need.
"These findings offer an incredible opportunity to ease suffering, make chemotherapy more effective, and give cancer patients the immune support for their body to fight back," said Yoshinobu Odaira (pictured), CEO and President of Shogun Maitake.
"I've dedicated my life to perfecting growing methods for Black Maitake mushrooms and supporting research behind unlocking the full potential of this natural extract to help eliminate cancer globally."